The Role of Intraarterial Chemotherapy in the Management of Retinoblastoma.
Discussion. The studies have shown that IAC is a safe and effective treatment for advanced retinoblastoma, especially group D. It allows to save the globe without compromising patients' survival. Local and systemic complications are acceptable. The role of IAC in less advanced tumours is yet to be established. Future work should focus on conducting larger prospective studies with longer follow-up. Multiple novel therapies for the management of retinoblastoma are currently being tested, including angiogenic inhibitors and targeted agents. The results seem to be promising. Future advances require a further in-depth understanding of unique genetics of retinoblastoma and complex interactions between tumour cells and their microenvironment. PMID: 32047660 [PubMed]
Conclusions: Our series showed that 6% of patients with retinoblastoma were 5 years of age and older. Over a 15-year period, ocular salvage rate of 11.2% and survival rate of 100% were attained. PMID: 32051765 [PubMed]
Conclusion: Intravitreal melphalan is a promising modality for treatment of vitreous seeds, and the dose of 20-30 μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds.μg of melphalan sounds to be safe and effective for refractory and recurrent vitreous seeds. PMID: 32047663 [PubMed]
Abstract BACKGROUND: Intravenous chemotherapy (IVC) remains an important globe salvage therapy for retinoblastoma. METHODS: Evaluation of long-term globe salvage at 5, 10, 15 and 20 years following frontline IVC for retinoblastoma. RESULTS: Of 994 eyes, comparison by International Classification of Retinoblastoma group (A vs B vs C vs D vs E) revealed more advanced group with older mean age at presentation (8 vs 7 vs 10 vs 11 vs 15 months, p
Conclusion: Profound morphometric disturbances that come with combined chemotherapy call for a more careful treatment with methods selected in terms of OCT findings and specific chemotherapy contraindications. PMID: 31922451 [PubMed - as supplied by publisher]
Publication date: Available online 10 January 2020Source: Journal of Pediatric Surgery Case ReportsAuthor(s): Ameer Kakaje, Osama Hosam Aldeen, Yousef Mahmoud, Othman HamdanAbstractRetino- and neuroblastoma are primitive neuroectodermal tumors which share common histology, and embryological origin. However, no apparent correlation was found that can link them both such as common genes. Our patient had retinoblastoma which was surgically treated with low-dose chemotherapy. After three years, he evolved a neuroblastoma despite the chances for this concurrence being less than 1 in 10 billion for having both tumors in one pati...
ConclusionsRosiglitazone combined with olaparib can help manage ovarian cancer by ameliorating olaparib-induced senescence and improving anti-tumor effects.
Conclusion: This case poses an outlook into a dilemma as to whether or not systemic chemotherapy should be started along with antiretroviral therapy for treating retinoblastoma, as there are no cited case reports in the literature of retinoblastoma coexisting with HIV and its related management regime and future considerations to be taken for management.
Conclusion: Ophthalmic vascular events after IAC for retinoblastoma affect only 5% of eyes per infusion (17% of treated eyes). Vascular event risk per eye is similar when using IAC as primary or secondary treatment.
Conclusion: Intravitreal anti–vascular endothelial growth factor contributed to a globe salvage rate of 51% by providing conditions to continue conservative treatment.
This case report describes a 17-month-old girl with group B retinoblastoma treated with cycles of chemotherapy.